JP2024520805A - アルツハイマー病の治療のための神経活性ステロイド - Google Patents

アルツハイマー病の治療のための神経活性ステロイド Download PDF

Info

Publication number
JP2024520805A
JP2024520805A JP2023575831A JP2023575831A JP2024520805A JP 2024520805 A JP2024520805 A JP 2024520805A JP 2023575831 A JP2023575831 A JP 2023575831A JP 2023575831 A JP2023575831 A JP 2023575831A JP 2024520805 A JP2024520805 A JP 2024520805A
Authority
JP
Japan
Prior art keywords
subject
compound
pharma
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520805A5 (https=
Inventor
ジェイムズ ジェイ． ドハーティ，
マイケル シー． クアーク，
アルバート ジーン ロビチャウド，
アーロン マイケル ケーニグ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2024520805A publication Critical patent/JP2024520805A/ja
Publication of JP2024520805A5 publication Critical patent/JP2024520805A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023575831A 2021-06-11 2022-06-10 アルツハイマー病の治療のための神経活性ステロイド Pending JP2024520805A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163209929P 2021-06-11 2021-06-11
US63/209,929 2021-06-11
US202163289081P 2021-12-13 2021-12-13
US63/289,081 2021-12-13
US202263321598P 2022-03-18 2022-03-18
US63/321,598 2022-03-18
PCT/US2022/033122 WO2022261510A1 (en) 2021-06-11 2022-06-10 Neuroactive steroid for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2024520805A true JP2024520805A (ja) 2024-05-24
JP2024520805A5 JP2024520805A5 (https=) 2025-06-30

Family

ID=82361350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575831A Pending JP2024520805A (ja) 2021-06-11 2022-06-10 アルツハイマー病の治療のための神経活性ステロイド

Country Status (9)

Country Link
US (1) US20250319105A1 (https=)
EP (1) EP4351588A1 (https=)
JP (1) JP2024520805A (https=)
KR (1) KR20240035444A (https=)
AU (1) AU2022291395A1 (https=)
CA (1) CA3223179A1 (https=)
IL (1) IL309208A (https=)
MX (1) MX2023014719A (https=)
WO (1) WO2022261510A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4704905A1 (en) * 2023-05-02 2026-03-11 Sage Therapeutics, LLC Lymphatic system-targeting compounds
TW202508603A (zh) * 2023-05-02 2025-03-01 美商賽吉醫療公司 神經活性類固醇調配物及其使用方法
WO2025021195A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025020191A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
HUE030100T2 (en) 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AP2014007606A0 (en) 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
HUE039922T2 (hu) 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
JP6272833B2 (ja) 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物
EP3102230B1 (en) * 2014-02-08 2021-04-28 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2991311C (en) 2015-07-06 2025-05-06 Sage Therapeutics, Inc. OXYSTEROLS AND THEIR METHODS OF USE
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
US10562881B2 (en) 2015-10-16 2020-02-18 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
CA3021634A1 (en) 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
CA3038984A1 (en) 2016-09-30 2018-04-05 Schlumberger Canada Limited Fiber measurements for fluid treatment processes in a well
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
TW202523658A (zh) 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
WO2022115620A1 (en) 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
WO2022261510A1 (en) 2022-12-15
KR20240035444A (ko) 2024-03-15
MX2023014719A (es) 2024-02-15
IL309208A (en) 2024-02-01
US20250319105A1 (en) 2025-10-16
CA3223179A1 (en) 2022-12-15
EP4351588A1 (en) 2024-04-17
AU2022291395A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
JP2024520805A (ja) アルツハイマー病の治療のための神経活性ステロイド
CN109563159B (zh) 抗c5抗体及其用途
JP6055055B2 (ja) ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
TWI798751B (zh) 抗－N3pGlu類澱粉β肽抗體及其用途
JP7368624B2 (ja) Ｔｒｅｍ２抗体およびそれらの使用
JP6685912B2 (ja) アルツハイマー病治療方法
US10988529B2 (en) Combination therapy
TW201716436A (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
JP2020007354A (ja) 抗血漿カリクレイン抗体
JP6913078B2 (ja) タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
HUE029824T2 (en) Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
KR20250152696A (ko) C1s에 결합하는 항체 및 이의 용도
US20240166765A1 (en) Inflammatory disease treatment using anti-tissue factor antibodies
US20220242943A1 (en) Anti- pdgf-b antibodies and methods of use for treating pulmonary arterial hypertension (pah)
CN117769425A (zh) 用于治疗阿尔茨海默氏病的神经活性类固醇
HK40110954A (en) Anti-c5 antibodies and uses thereof
HK40001079B (en) Anti-c5 antibodies and uses thereof
HK40001079A (en) Anti-c5 antibodies and uses thereof
HK1166509B (en) High affinity human antibodies to human protease-activated receptor-2

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620